CN104487569A - 间充质干细胞的成骨分化 - Google Patents
间充质干细胞的成骨分化 Download PDFInfo
- Publication number
- CN104487569A CN104487569A CN201380028009.7A CN201380028009A CN104487569A CN 104487569 A CN104487569 A CN 104487569A CN 201380028009 A CN201380028009 A CN 201380028009A CN 104487569 A CN104487569 A CN 104487569A
- Authority
- CN
- China
- Prior art keywords
- cell
- target cell
- extracellular
- ectosome
- osteoblast differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009818 osteogenic differentiation Effects 0.000 title abstract 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000001737 promoting effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 133
- 210000002583 cell-derived microparticle Anatomy 0.000 claims description 78
- 210000000130 stem cell Anatomy 0.000 claims description 42
- 210000001616 monocyte Anatomy 0.000 claims description 38
- 230000004072 osteoblast differentiation Effects 0.000 claims description 29
- 239000007943 implant Substances 0.000 claims description 26
- 230000006698 induction Effects 0.000 claims description 18
- 208000002352 blister Diseases 0.000 claims description 15
- 210000000988 bone and bone Anatomy 0.000 claims description 14
- 239000002158 endotoxin Substances 0.000 claims description 14
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 239000002516 radical scavenger Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 102000019034 Chemokines Human genes 0.000 claims description 7
- 108010012236 Chemokines Proteins 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 210000004969 inflammatory cell Anatomy 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000011800 void material Substances 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 206010061363 Skeletal injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000009283 Craniosynostoses Diseases 0.000 claims description 2
- 206010049889 Craniosynostosis Diseases 0.000 claims description 2
- 210000004394 hip joint Anatomy 0.000 claims description 2
- 210000003127 knee Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 239000003636 conditioned culture medium Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 102000013275 Somatomedins Human genes 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 8
- 102100025222 CD63 antigen Human genes 0.000 description 7
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102100027221 CD81 antigen Human genes 0.000 description 5
- 102100037904 CD9 antigen Human genes 0.000 description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 5
- -1 IL-14 Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 3
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000008568 cell cell communication Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000003126 immunogold labeling Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000002642 osteogeneic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000004454 trace mineral analysis Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102000034342 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 101710181549 Interleukin-34 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108700030796 Tsg101 Proteins 0.000 description 1
- 101150072717 Tsg101 gene Proteins 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Pain & Pain Management (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种使用细胞外小泡用于诱导和/或促进成骨分化的方法及其用途。
Description
技术领域
本发明涉及一种诱导或促进细胞分化的方法,用于在诱导或促进所述分化中使用的细胞外小泡,所述小泡的用途以及一种使用所述小泡的治疗方法。
背景技术
在植入物表面处或在损伤部位处的早期骨形成的机制以及影响骨-植入物接触、稳定性和功能的维持的因素未得到完全理解。炎性细胞和干细胞与祖细胞在植入物的表面上通讯的途径的增加的知识对于理解应该如何优化下一代用于临床使用的植入物而言是重要的。伴随更多的知识,在将来,我们将有希望能够生产用于改进的骨整合的新的且更好的植入物或用于骨愈合的更好的药物。
单核细胞/巨噬细胞系统在宿主防御、伤口愈合以及生物材料表面处的免疫调控上发挥核心作用。单核细胞和间充质干细胞迅速迁移至植入的材料表面并且在细胞外基质沉积和骨形成之前被定位成彼此靠近。已经显示,来自人类单核细胞,包含例如促炎细胞因子的条件培养基促进人类间充质干细胞(hMSC)的成骨分化。单核细胞如何与MSC通讯未被完全确定,尽管已经提议它们在不存在直接的细胞间接触的情况下通讯。
细胞外小泡(EV)(包括外体)在细胞间通讯中发挥重要作用。细胞间通讯的一种提议的普遍机理涉及经由外体传递而递送RNA,很可能发生在微环境中但是潜在地还可能发生在远处。外体是内吞起源的小膜泡(40-100nm),当多泡体与质膜融合时,其被释放进细胞外环境中。外体提供了一种细胞之间的通讯方式,其中一个细胞可以释放在微环境中或在一段距离上可以影响其他细胞的外体。外体释放自许多细胞并且其功能取决于细胞起源以及给予外体其特征性组成的产生细胞的情况。例如,起源自暴露于氧化应激的细胞的外体显示出赋予对抗受体细胞中的应激的保护性信息。
然而,对EV是否及如何影响受体细胞的分化所知甚少。
发明内容
本发明的目的是提供一种用于诱导和/或促进细胞的成骨分化的方法,优选是间充质干细胞,更优选是人类间充质干细胞(hMSC)。本发明还涉及细胞外小泡用于增加骨再生及用于支持植入物的骨整合的用途。
在一个第一方面中,本发明涉及一种诱导和/或促进靶标干细胞的成骨分化的方法,该方法包括:
a.提供来自非靶标细胞的细胞培养物的条件培养基或分离自非靶标细胞的细胞外小泡;并且
b.将该培养基或这些细胞外小泡添加至这些靶标干细胞中。
在一个第二方面中,本发明涉及用于在靶标干细胞的成骨分化中使用的分离的细胞外小泡。
在一个第三方面中,本发明涉及一种培养基,该培养基包括由非靶标细胞获得的用于在靶标干细胞的成骨分化中使用的细胞外小泡。
在一个第四方面中,本发明涉及一种植入物表面,该表面包括一种暴露于细胞外小泡的涂层。
在一个第五方面中,本发明涉及一种植入物表面,该表面包括一种固定的经刺激的单核细胞、巨噬细胞或间充质干细胞的涂层,这些细胞能够产生外体。
在一个第六方面中,本发明涉及一种治疗患者的方法,该方法包括从该患者收集血液或组织样品,分离非靶标细胞,培养并刺激这些非靶标细胞,分离由这些非靶标细胞产生的外体并且将这些外体给予至该患者。
在一个第七方面中,本发明涉及分离的细胞外小泡用于治疗骨损伤、骨质疏松、骨发生或在骨固定中的用途。
在一个第八方面中,本发明涉及一种组合物,该组合物包括用于治疗骨损伤、骨空隙、骨质疏松或骨发生的分离的细胞外小泡。
在一个第九方面中,本发明涉及一种骨空隙填充物,该填充物包括分离的细胞外小泡。
附图说明
图1.从人类单核细胞细胞系HMC-1的条件培养基分离的并且经针对CD63免疫金标记的外体的透射电镜术图片。
图2.与抗-CD63乳胶珠粒轭合的从单核细胞衍生的外体的流式细胞术分析。将外体针对四次跨膜蛋白CD9、CD63和CD81(右图)以及同型匹配的对照(左图)进行免疫染色。
图3.从单核细胞外体及其供体细胞提取的蛋白质的蛋白质印迹分析。
图4.对来自单核细胞的外体的和细胞的总RNA和小RNA进行检测。电泳图谱披露了(a)单核细胞外体和细胞(b)中的总RNA以及外体(c)和细胞(d)中的小RNA的核苷酸大小分布(nt)和荧光强度(FU)。
图5.将流式细胞术分析(与用于单核细胞外体的类似)应用于从间充质干细胞中检测外体。数据显示间充质干细胞释放对于CD9、CD63和CD81呈阳性的外体。
图6.MSC外体的纳米颗粒跟踪分析。
图7.用针对CD63的免疫金标记的MSC外体的透射电镜术图片(条20nm)。
图8.电泳图谱披露了MSC和分离自MSC培养物的外体的总RNA的核苷酸大小分布(nt)和荧光强度(FU)。
图9.MSC外体向单核细胞的转移
将MSC外体分离,用一种绿色荧光染料(PKH67,西格玛(SIGMA))标记并且添加至培养物中的单核细胞里。24h后,通过(a)流式细胞仪和(b)荧光显微镜对标记的小泡的摄取进行分析。对照;PKH6染色的PBS。将DAPI用于细胞核染色。绿色细胞是对绿色外体呈阳性的单核细胞,显示它们已经摄取外体或附接至其表面的外体。
图10.MSC外体向MSC的转移与图9中的类似,将MSC外体分离,用一种绿色荧光染料(PKH67,西格玛)标记并且添加至MSC培养物中。24h后,通过(a)流式细胞仪和(b)荧光显微镜对摄取进行分析。对照;PKH6染色的PBS。将DAPI用于细胞核染色。绿色细胞是对绿色外体呈阳性的MSC,显示它们已经摄取外体或附接至其表面的外体。
图11.将释放自用LPS刺激的单核细胞/巨噬细胞的外体分离,用一种绿色荧光染料(PKH67,西格玛)标记并且添加至培养中的MSC里。将MSC在绿色外体的存在下培养大约72h,然后通过流式细胞仪(a)在荧光显微镜(b)中对细胞进行分析。将DAPI用于细胞核染色。绿色细胞是对绿色外体呈阳性的MSC,显示它们已经摄取外体或附接至其表面的外体。来自单核细胞/巨噬细胞的外体被摄取/附接至间充质干细胞。
图12.在hMSC中培养72h的Runx2和BMP-2在非条件对照培养基(对照)、在单核细胞条件培养基(CM)或在补充有外体的培养基(外体)中的基因表达。
具体实施方式
在本发明中,术语“一个靶标干细胞”或“多个靶标干细胞”意指有待被条件培养基或来自非靶标细胞的额外的细胞小泡诱导成骨分化的一个细胞或多个细胞。
术语“条件培养基”意指在已经除去培养的细胞后用于细胞培养的培养基。
通常将至细胞的信号传导认为是以可溶态呈现的和/或表面上的分子的作用,是与细胞的质膜或基质相关的。本发明涉及由细胞来源的,大约20-400nm或50-200nm,包含例如蛋白质、mRNA和微小RNA的细胞外小泡介导的细胞间通讯。这些小泡附接至、融合至靶标细胞或被靶标细胞内化并且在靶标细胞中发挥调控作用。这种通讯可以诱导和/或促进细胞(例如干细胞,尤其是人类间充质干细胞)的成骨分化。
诸位发明人已经开发了一种诱导和/或促进靶标细胞的成骨分化的方法。该方法包括提供来自非靶标细胞的细胞培养物的条件培养基或释放自非靶标细胞的分离的细胞外小泡。在一个实施例中,这些细胞外小泡是外体。这些额外的细胞小泡是通过培养非靶标细胞,任选地在非靶标细胞的刺激以释放所述小泡以及条件培养基或小泡的分离的过程中提供。可以将这些非靶标细胞培养不同时间,例如1小时或更久、或1天或更久、或2天或更久、或3天或更久。将该培养基或这些小泡添加至或接触可以是干细胞的靶标细胞。然后,这些小泡被诱导和/或促进成骨分化的靶标细胞摄取或附接其上。
这些靶标细胞可以是任何适合的细胞类型或细胞系,但是也可以是祖细胞或干细胞。这些细胞可以例如是成骨细胞、破骨细胞、肥大细胞、肌细胞、脂肪细胞或间充质干细胞(MSC)(例如人类MSC)。
据诸位发明人所知,没有描述经由细胞外体或具有类似特性的其他细胞外小泡的细胞之间的相互作用(cross-talk)的公开案,这些细胞是例如炎性细胞和靶标细胞(例如间充质干细胞),该相互作用用于诱导和/或促进成骨分化。诸位发明人已经发现,细胞(如炎性细胞)向其他细胞(如间充质干细胞)发送信息,导致骨分化基因在受体细胞(例如干细胞)中的增加的表达。这些信息是外体和/或其他细胞外小泡。
根据本发明的靶标干细胞的成骨分化的诱导和/或促进可以通过刺激除靶标细胞以外的细胞(在此称为非靶标细胞)而进行。这些刺激的非靶标细胞可以是任何适合的细胞并且可以例如是单核细胞、巨噬细胞、红细胞、破骨细胞、肥大细胞、成肌细胞、角质形成细胞、脂肪细胞或任何其他炎性细胞或非炎性细胞以及干细胞(例如间充质干细胞)。优选地,这些非靶标细胞是单核细胞、巨噬细胞或干细胞,并且在一个优选实施例中,这些非靶标细胞是人类单核细胞、巨噬细胞或干细胞(例如hMSC)。该方法可以在体内和体外进行。
不被理论所束缚,这些靶标细胞或非靶标细胞的表型在诱导和/或促进成骨分化的成功中可以发挥一定作用。已知的是,来自具有不同表型的非靶标细胞的EV也具有不同表型和功能。此外,这些靶标细胞的表型可以影响EV是否可以结合至并且将其信息递送至靶标细胞,并且进一步影响该靶标细胞是否可以被定向在一个特定方向上。在本发明的一个实施例中,这些非靶标细胞是自体的或非自体的。在另一个实施例中,这些靶标细胞是自体的或非自体的。使用自体的益处可以是有限的免疫应答,而来自健康个体或未罹患有待治疗的疾病的个体的非自体细胞在其达到再生或愈合过程时可以是有益的。
能以多种方式刺激这些细胞,例如通过使用一种刺激剂,如脂多糖(LPS)、细胞因子、趋化因子或任何其他刺激物或其组合。刺激剂的量的范围可以是1至100ng/ml,例如1ng/ml或更多、或5ng/ml或更多、或10ng/ml或更多、或20ng/ml或更多、或100ng/ml或更少、或70ng/ml或更少、或50ng/ml或更少、或30ng/ml或更少。在一个实施例中,刺激剂的浓度范围是1至20ng/ml,在另一个实施例中,该浓度是5至50ng/ml,并且在又另一个实施例中,该浓度是5至15ng/ml。
不被理论所束缚,认为非靶标细胞(尤其是刺激的非靶标细胞)产生额外的分化刺激细胞小泡(释放自细胞的膜的小囊,例如外体),当与靶标干细胞接触或被其摄取时,这些小泡诱导成骨分化。这些小泡(诱导和/或促进成骨分化小泡)可以分离自来自非靶标细胞中的任一个的条件培养基,这些非靶标细胞是例如单核细胞、巨噬细胞、红细胞、破骨细胞、肥大细胞、脂肪细胞以及干细胞(例如间充质干细胞)。这些小泡可以与其他生物分子(例如生长因子)混合。这些细胞外小泡的大小的范围可以是20至400nm,例如20nm或更大、或50nm或更大、或80nm或更大、或100nm或更大、或400nm或更小、或300nm或更小、或250nm或更小、或200nm或更小、或150nm或更小。图1披露了分离自条件培养基的外体。
在一个实施例中,这些分离的EV是释放自两种或更多种不同细胞类型的EV的组合。在另一个实施例中,这些分离的EV是释放自使用两种或更多种不同类型的刺激剂刺激的细胞的EV的组合。在又另一个实施例中,这些分离的EV是释放自两种或更多种不同细胞类型的EV的组合,其中使用至少一种不同类型的刺激剂对每种细胞类型进行刺激。
负责分化的细胞因子、生长因子或其他信号物质或物质的组合仍未被完全确定。这些细胞因子、生长因子和其他信号物质也可以用来刺激这些非靶向细胞,以释放例如具有一种特定表型和/或功能的细胞外小泡。其他信号物质可以例如是激素。潜在的细胞因子是IL-1、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-11、IL-12、IL-13、IL-14、IL-15、IL-16、IL-17、IL-18、Il-19、IL-20、IL-21、IL-22、IL-23、IL-24、IL-25、IL-26、IL-27、IL-28、IL-29、IL-30、IL-31、IL-32、IL-33、IL-34、IL-35或IFN-类型,或其组合。潜在的生长因子是BMP、TGF、VEGF、TNF或FGF或其组合。趋化因子的实例将是类型CC、CXC、CX3C及XC中的任一种,例如CCL 2、CCL 3、CCL 5、CCL 7、CCL 8、CCL11、CCL 13、CCL 17、CCL 22、CCL 24、CCL 26、CCR1、CCR2、CCR3、CCR4、CCR5或其组合。其他信号物质可以例如是激素。
这些小泡可以进一步包括其他物质,例如其他蛋白质、生长因子(BMP、TGF、VEGF、TNF或FGF或其组合)、mRNA、miRNA或siRNA或其他调控小RNA。
在一个实施例中,使用脂多糖(LPS)、细胞因子、趋化因子、生长因子(BMP、TGF、VEGF、TNF或FGF或其组合)或任何其他刺激物或其组合刺激这些非靶向细胞,以释放包含蛋白质、生长因子(BMP、TGF、VEGF、TNF或FGF或其组合)、mRNA、miRNA或siRNA或其他调控小RNA或其组合的额外的细胞小泡。
在又另一个实施例中,使用脂多糖(LPS)、细胞因子、趋化因子、生长因子(BMP、TGF、VEGF、TNF或FGF或其组合)或任何其他刺激物或其组合刺激这些非靶向细胞,以释放包含蛋白质、生长因子(BMP、TGF、VEGF、TNF或FGF或其组合)、mRNA、miRNA或siRNA或其他调控小RNA或其组合的额外的细胞小泡。然后,将这些小泡添加至或接触靶标细胞,这些靶标细胞与脂多糖(LPS)、细胞因子、趋化因子、生长因子或任何其他刺激物或其组合处于组合形式。
诸位发明人已经证明,MSC和单核细胞两者都释放包含RNA的细胞外小泡(图1-8),并且诸位发明人还已经证明,靶标MSC摄取释放的细胞外小泡(图9-10)。诸位发明人还已经证明,当根据本发明处理hMSC时,成骨分化被促进,如通过RUNX2和BMP-2的增加的基因表达所示例(图12)。
可以将这些细胞外小泡与一种例如PBS缓冲液或任何其他盐水缓冲液或任何其他培养基的细胞培养基(或条件培养基)混合。该培养基可以包含来自多于一种类型的非靶标细胞(例如两种、三种或四种细胞类型)的小泡。例如,该培养基可以包含来自单核细胞和hMSC,或单核细胞、hMSC和巨噬细胞的小泡的混合物。这些细胞外小泡可以在体外和体内提供给靶标细胞。
可以将来自非靶标细胞培养物的条件培养基或分离的细胞外小泡添加至需要骨再生的部位。该条件培养基或这些小泡也可以与靶标细胞一起被递送。通过将该培养基或这些小泡递送至靶标细胞定位的部位,成骨分化将得以诱导。可以通过注射或经由递送运载体的植入进行递送。与例如合成脂质体相比,细胞外小泡(例如外体)具有导致中度免疫应答或不导致免疫应答的益处。
将这些细胞外小泡以足够诱导和/或促进成骨分化的量添加至或接触靶标细胞。
此外,可以通过将这些小泡涂层或固定在表面上,例如在植入物的表面上,或作为药物递送系统的一部分来将这些小泡提供给干细胞。该植入物表面可以是一种金属表面(例如钛或氧化钛)或一种陶瓷表面(例如磷酸钙表面)。该药物递送系统可以例如是一种将缓慢释放这些小泡的水凝胶或生物降解材料。该水凝胶可以例如是透明质酸或壳聚糖或聚乙烯醇或其组合。在另一个实施例中,利用用于体内释放细胞外小泡的细胞涂覆或固定植入物表面。例如,可以用可释放增加数目的外体的经刺激的单核细胞、巨噬细胞或间充质干细胞涂覆或固定表面,以在植入物部位处诱导和/或促进成骨分化。
根据本发明的方法还可以用于治疗患者。该方法包括
-使用任何可得的适合技术从人(例如该患者本人)中收集血液或组织样品;
-分离非靶标细胞并且培养这些细胞并且任选地刺激这些非靶标细胞,以产生诱导和/或促进细胞外小泡;
-分离由这些非靶标细胞产生的所述细胞外小泡;并且
-向该患者给予这些细胞外小泡。
可以通过任何适合的技术全身地或局部地进行给予,例如通过至需要或想要成骨分化的位置的注射器。
可以将本发明用作骨外科、植入物外科、骨愈合治疗或骨或牙齿固定治疗过程中的辅助治疗。可以将这些分离的细胞外小泡固定在不同支架和植入物上,例如用于牙科应用(例如牙齿)、髋关节或膝盖的植入物或任何其他骨植入物。还可以将这些小泡固定在骨固定植入物(例如螺钉或固定板)上。此外,本发明可以用于治疗各种骨有关疾病和损伤,例如骨空隙填充材料、骨赘、颅缝早闭、骨关节炎,各种骨病、骨硬化、骨质疏松或骨发生。
实例
实例1
过程的一般描述
单核细胞的分离与培养:使用磁力分离从人类血液中分离单核细胞并且在不同生物材料上进行培养并且用或不用刺激(例如LPS)。间充质干细胞是通过梯度分离获得自人类骨髓。72h后,收获细胞并且从条件培养基中分离外体。
外体分离与检测:将使用以下的方法分离外体,该方法是基于重复的离心与过滤步骤以除去细胞碎片、凋亡小体等,随后超速离心以沉淀外体。还可以使用替代性分离方法。将使用包括电子显微术以及使用流式细胞术和蛋白质印迹法检测多种标记物的方法的组合来检测外体,这些标记物是通常发现于外体上的标记物(例如CD9、CD63、CD81、Tsg101)和应该不存在于外体中的标记物(钙联蛋白)。
外体的mRNA与微小RNA含量:将在来自暴露于不同刺激的单核细胞和MSC的外体上进行微阵列,以评估mRNA与微小RNA含量。
摄取实验:将分离的外体用一种荧光染料标记,添加至培养中的MSC里并且在不同时间点后使用荧光显微术和流式细胞术对摄取进行分析。
骨发生的评估:使用RT-PCR对组织学染色(冯·科萨法(von Kossa))和骨形成的标记物(骨钙素,runx2,I型胶原)进行评估。
材料与方法
人类单核细胞是通过磁力分离获得自血沉棕黄层(纯度90%-95%,n=4)。将这些单核细胞用LPS(10ng/ml)处理72h并且将条件培养基(CM)进行收集。对人类脂肪来源的间充质干细胞(MSC)进行培养并且将条件培养基进行收集。将外体通过重复的离心与过滤步骤从CM中分离并且使用流式细胞术进行检测。对于流式细胞术分析,将外体与抗-CD63乳胶珠粒进行轭合并且针对四次跨膜蛋白CD9、CD63和CD81进行免疫染色。还使用透射电镜术和纳米颗粒跟踪分析将外体可视化。提取来自不同类型的小泡及其供体细胞的RNA并且使用一个生物分析仪分析大小分布图案。将hMSC在补充有单核细胞外体的培养基、CM或对照培养基中培养72h。使用实时PCR分析评估成骨分化(Runx2,BMP-2,n=4)。通过dd-Ct方法计算靶标基因表达的相对定量。在单独的实验中,将人类单核细胞或hMSC在补充有PKH67染色的小泡的培养基中进行培养并且使用流式细胞术和显微术对摄取进行检查。
结果
流式细胞术分析揭示,LPS-刺激的单核细胞和MSC释放对于四次跨膜蛋白CD9、CD63和CD81呈阳性的外体,这些四次跨膜蛋白是通常用于外体检测的标记物,参见图2和5。
图11披露了来自单核细胞/巨噬细胞的外体被摄取/附接至间充质干细胞。与阴性对照相比,在绿色PKH67染色的外体的存在下培养的MSC在FL-1中是阳性的,表明这些外体附接至或与MSC融合或被MSC内化。此外,在补充有PKH67标记的绿色MSC外体的培养基中培养hMSC显示MSC对该绿色染料呈阳性,说明MSC经由外体与其他MSC通讯,参见图10。另外,用绿色MSC外体培养单核细胞也揭示,一部分单核细胞已经摄取或内化绿色外体,参见图9。
与对照培养基相比,在单核细胞CM或在补充有分离自CM的纯外体的培养基中培养hMSC持续72h,导致Runx2(倍数变化,分别是1.7±0.3和1.4±0.2)和BMP-2(倍数变化,分别是15.4±1.7和2.3±0.3)的显著增加的表达水平,参见图12。
这些结果证明,LPS-刺激的人类单核细胞释放增强间充质干细胞的成骨分化的因子并且这种作用的至少一部分归因于经由外体的通讯。
实例2
人类初级LPS刺激的单核细胞。培养3天后,分离外体并且提取RNA。对细胞的和外体的总RNA和小RNA进行生物分析器分析。电泳图谱示出了(图4)(a)外体和细胞(b)中的总RNA以及外体(c)和细胞(d)中的小RNA的核苷酸大小分布(nt)和荧光强度(FU)。
Claims (20)
1.一种诱导和/或促进靶标细胞的成骨分化的方法,该方法包括:
a.提供释放自非靶标细胞的诱导和/或促进成骨分化分离的细胞外小泡;并且
b.将这些细胞外小泡添加至这些靶标细胞中。
2.如权利要求1所述的方法,其中这些非靶标细胞是刺激的单核细胞、巨噬细胞或间充质干细胞或其他炎性或非炎性细胞。
3.如权利要求2所述的方法,其中用脂多糖、细胞因子、趋化因子或任何其他刺激物刺激这些非靶标细胞。
4.如权利要求2所述的方法,其中以任何其他方式刺激或修饰这些非靶标细胞,以释放诱导和/或促进间充质干细胞的成骨分化的细胞外小泡。
5.如权利要求1至4中任一项所述的方法,其中这些细胞外小泡释放自单核细胞。
6.如权利要求1至4中任一项所述的方法,其中提供的这些小泡是释放自两种或更多种不同类型的细胞的小泡的组合,或释放自使用两种或更多种不同类型的刺激剂刺激的细胞的小泡的组合,或释放自两种或更多种不同细胞类型的EV的组合,其中使用至少一种不同类型的刺激剂刺激每个细胞类型。
7.如以上权利要求中任一项所述的方法,其中这些细胞外小泡是外体。
8.来自非靶标细胞的分离的诱导和/或促进成骨分化细胞外小泡用于靶标细胞的成骨分化的用途。
9.根据权利要求8所述的小泡,其中这些非靶标细胞是经刺激的单核细胞、巨噬细胞或间充质干细胞或其他炎性或非炎性细胞。
10.根据权利要求9所述的小泡,其中用脂多糖、细胞因子、趋化因子或任何其他刺激物刺激这些非靶标细胞。
11.根据权利要求8至10中任一项所述的小泡,其中这些小泡是外体。
12.根据权利要求8至11中任一项所述的小泡,其中这些小泡悬浮于一种培养基中。
13.一种植入物,该植入物包括一种暴露于诱导和/或促进成骨分化细胞外小泡的涂层。
14.一种植入物,该植入物包括一种固定的经刺激的单核细胞、巨噬细胞或间充质干细胞的涂层,这些细胞能够产生诱导和/或促进成骨分化细胞外小泡。
15.根据权利要求13或14中任一项所述的植入物,其中该植入物是一种用于牙科应用、髋关节、膝盖的植入物、螺钉或固定板。
16.根据权利要求8至12中任一项用于治疗损伤、骨质疏松、骨发生或在骨固定中的用途。
17.一种组合物,该组合物包括分离的诱导和/或促进成骨分化细胞外小泡,这些细胞外小泡用于治疗骨损伤、骨空隙填充材料、骨赘、颅缝早闭、骨关节炎、各种骨病、骨质疏松或骨发生。
18.一种骨空隙填充物,该骨空隙填充物包括分离的诱导和/或促进成骨分化细胞外小泡。
19.根据权利要求18所述的骨空隙填充物,进一步包括靶向干细胞。
20.一种治疗患者的方法,该方法包括从该患者收集血液或组织样品,分离非靶标细胞,培养并刺激这些非靶标细胞,分离由这些非靶标细胞产生的细胞外小泡并且将这些细胞外小泡给予至该患者。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1250477-5 | 2012-05-10 | ||
SE1250477 | 2012-05-10 | ||
PCT/SE2013/050526 WO2013169202A1 (en) | 2012-05-10 | 2013-05-10 | Osteogenic differentiation of mesenchymal stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104487569A true CN104487569A (zh) | 2015-04-01 |
Family
ID=49551066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380028009.7A Pending CN104487569A (zh) | 2012-05-10 | 2013-05-10 | 间充质干细胞的成骨分化 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150093363A1 (zh) |
EP (1) | EP2847320A4 (zh) |
JP (1) | JP2015523058A (zh) |
CN (1) | CN104487569A (zh) |
WO (1) | WO2013169202A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106047802A (zh) * | 2016-06-15 | 2016-10-26 | 北京大学口腔医院 | 一种促进间充质干细胞成骨分化的材料及其制备方法和应用 |
CN112190596A (zh) * | 2020-09-14 | 2021-01-08 | 陕西佰傲干细胞再生医学有限公司 | 一种用于治疗关节炎的间充质干细胞制剂及其制备方法 |
CN112423773A (zh) * | 2018-05-15 | 2021-02-26 | 鹿特丹伊拉斯谟大学医疗中心 | 用于寨卡病毒感染预后的治疗和生物标志物 |
CN113440653A (zh) * | 2021-07-01 | 2021-09-28 | 山西医科大学口腔医院 | 一种促进骨结合的钛基种植体及其制备方法和应用 |
WO2023185066A1 (zh) * | 2022-04-01 | 2023-10-05 | 北京大学口腔医学院 | 一种人红细胞制备凋亡囊泡的方法与应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
US20160120805A1 (en) * | 2013-06-05 | 2016-05-05 | The Trustees Of Columbia University In The City Of New York | Exosomes for orofacial diagnostics and therapeutics |
WO2016157142A1 (en) * | 2015-04-02 | 2016-10-06 | Stegi-Ra Trust | Composition for use in treating celiac disease |
JP6875297B2 (ja) * | 2015-06-09 | 2021-05-19 | オーソサイト コーポレイション | 骨形成性移植片形成ユニット |
WO2016203414A1 (en) * | 2015-06-16 | 2016-12-22 | Fondazione Città Della Speranza - Onlus | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use |
WO2016210256A1 (en) * | 2015-06-25 | 2016-12-29 | The University Of Florida Research Foundation, Inc. | Conductive nonwoven mat and method of using the conductive nonwoven mat |
WO2017189842A1 (en) * | 2016-04-27 | 2017-11-02 | The Scripps Research Institute | Extracellular vesicles from young stem cells or serum for age-related therapies |
FR3055805B1 (fr) * | 2016-09-09 | 2020-05-15 | Assistance Publique - Hopitaux De Paris (Ap-Hp) | Biomateriau a usage therapeutique |
WO2018115871A1 (en) * | 2016-12-20 | 2018-06-28 | The University Of Birmingham | Composition and method for bone production |
CN108324735B (zh) * | 2017-01-20 | 2024-02-09 | 李莉 | 用于疾病治疗的胞外体制剂及其应用 |
KR20190011213A (ko) * | 2017-07-24 | 2019-02-01 | 한양대학교 에리카산학협력단 | 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물 |
EP3801589B1 (en) * | 2018-06-01 | 2024-08-28 | Memorial Sloan Kettering Cancer Center | Methods and compositions for the treatment of osteopetrosis |
WO2020081859A1 (en) * | 2018-10-18 | 2020-04-23 | Nantbio, Inc. | Mesenchymal stem cell derived exosomes and methods |
CN109568665B (zh) * | 2018-12-28 | 2021-12-10 | 中国医科大学附属第一医院 | 负载脂肪干细胞外泌体的温敏型可注射水凝胶及其制备方法和应用 |
CN112175899A (zh) * | 2019-07-04 | 2021-01-05 | 陕西佰傲干细胞再生医学有限公司 | 间充质干细胞成骨定向分化诱导液及其应用 |
CN110951685A (zh) * | 2019-10-28 | 2020-04-03 | 天津市康婷生物工程集团有限公司 | 一种应用于间充质干细胞成骨分化的单核细胞源外泌体制剂 |
KR102184428B1 (ko) * | 2020-05-25 | 2020-11-30 | 주식회사 씨케이엑소젠 | 중배엽줄기세포 유래의 엑소좀 생산방법 및 이로부터 제조된 배양액 |
KR20220033444A (ko) * | 2020-09-09 | 2022-03-16 | 주식회사 셀렉소바이오 | 경막외 지방 중간엽 줄기세포 유래 엑소좀을 포함하는 골 질환 치료용 조성물 |
WO2023212637A1 (en) * | 2022-04-29 | 2023-11-02 | CryoHeart Laboratories, Inc. | Systems, methods, and devices of exosome delivery for filling bone fracture voids |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082511A1 (en) * | 2001-01-18 | 2004-04-29 | Georg Watzek | Drug composition for the promotion of tissue regeneration |
US20090007923A1 (en) * | 2000-10-06 | 2009-01-08 | Michael Dancu | System and method for controlling the diameter of a mammilian hybrid coronary bypass graft |
WO2009087361A1 (en) * | 2008-01-04 | 2009-07-16 | Lydac Neuroscience Limited | Microvesicles |
CN102232970A (zh) * | 2010-04-22 | 2011-11-09 | 董运海 | 一种治疗骨损伤细胞注射剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101636041B (zh) * | 2008-07-24 | 2011-05-11 | 富葵精密组件(深圳)有限公司 | 基板表面平坦化系统及基板表面平坦化方法 |
JP2013537538A (ja) * | 2010-08-13 | 2013-10-03 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー | 微小水泡および関連するマイクロrnaの治療用途 |
-
2013
- 2013-05-10 WO PCT/SE2013/050526 patent/WO2013169202A1/en active Application Filing
- 2013-05-10 EP EP13786931.9A patent/EP2847320A4/en not_active Withdrawn
- 2013-05-10 US US14/398,896 patent/US20150093363A1/en not_active Abandoned
- 2013-05-10 JP JP2015511419A patent/JP2015523058A/ja active Pending
- 2013-05-10 CN CN201380028009.7A patent/CN104487569A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090007923A1 (en) * | 2000-10-06 | 2009-01-08 | Michael Dancu | System and method for controlling the diameter of a mammilian hybrid coronary bypass graft |
US20040082511A1 (en) * | 2001-01-18 | 2004-04-29 | Georg Watzek | Drug composition for the promotion of tissue regeneration |
WO2009087361A1 (en) * | 2008-01-04 | 2009-07-16 | Lydac Neuroscience Limited | Microvesicles |
CN102232970A (zh) * | 2010-04-22 | 2011-11-09 | 董运海 | 一种治疗骨损伤细胞注射剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
OMAR M. OMAR ET AL.: "The stimulation of an osteogenic response by classical monocyte activation", 《BIOMATERIALS》 * |
TOMOHIRO ITOH ET AL.: "Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation", 《J MOL HIST》 * |
WEI ZHOU ET AL.: "The performance of bone marrow mesenchymal stem cell – Implant complexes prepared by cell sheet engineering techniques", 《BIOMATERIALS》 * |
刘伟等: "人骨髓间充质干细胞的体外培养、鉴定及成骨分化", 《中国组织工程研究》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106047802A (zh) * | 2016-06-15 | 2016-10-26 | 北京大学口腔医院 | 一种促进间充质干细胞成骨分化的材料及其制备方法和应用 |
CN106047802B (zh) * | 2016-06-15 | 2019-07-02 | 北京大学口腔医院 | 一种促进间充质干细胞成骨分化的材料及其制备方法和应用 |
CN112423773A (zh) * | 2018-05-15 | 2021-02-26 | 鹿特丹伊拉斯谟大学医疗中心 | 用于寨卡病毒感染预后的治疗和生物标志物 |
CN112190596A (zh) * | 2020-09-14 | 2021-01-08 | 陕西佰傲干细胞再生医学有限公司 | 一种用于治疗关节炎的间充质干细胞制剂及其制备方法 |
CN113440653A (zh) * | 2021-07-01 | 2021-09-28 | 山西医科大学口腔医院 | 一种促进骨结合的钛基种植体及其制备方法和应用 |
WO2023185066A1 (zh) * | 2022-04-01 | 2023-10-05 | 北京大学口腔医学院 | 一种人红细胞制备凋亡囊泡的方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2847320A4 (en) | 2015-12-30 |
WO2013169202A1 (en) | 2013-11-14 |
US20150093363A1 (en) | 2015-04-02 |
JP2015523058A (ja) | 2015-08-13 |
EP2847320A1 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104487569A (zh) | 间充质干细胞的成骨分化 | |
Bei et al. | Bone‐a‐petite: engineering exosomes towards bone, osteochondral, and cartilage repair | |
Ma et al. | Multilayer injectable hydrogel system sequentially delivers bioactive substances for each wound healing stage | |
Sadowska et al. | Inflammation and biomaterials: role of the immune response in bone regeneration by inorganic scaffolds | |
Zhang et al. | Electrical stimulation of adipose‐derived mesenchymal stem cells and endothelial cells co‐cultured in a conductive scaffold for potential orthopaedic applications | |
Qiao et al. | Magnesium-doped nanostructured titanium surface modulates macrophage-mediated inflammatory response for ameliorative osseointegration | |
Wang et al. | The odontogenic differentiation of human dental pulp stem cells on nanofibrous poly (L-lactic acid) scaffolds in vitro and in vivo | |
Ye et al. | A thermoresponsive polydiolcitrate-gelatin scaffold and delivery system mediates effective bone formation from BMP9-transduced mesenchymal stem cells | |
Li et al. | Tuning the surface potential to reprogram immune microenvironment for bone regeneration | |
Wu et al. | MicroRNA functionalized microporous titanium oxide surface by lyophilization with enhanced osteogenic activity | |
Muzzio et al. | Multifunctional scaffolds and synergistic strategies in tissue engineering and regenerative medicine | |
Wang et al. | Microarc-oxidized titanium surfaces functionalized with microRNA-21-loaded chitosan/hyaluronic acid nanoparticles promote the osteogenic differentiation of human bone marrow mesenchymal stem cells | |
Jiang et al. | Bone response to the multilayer BMP‐2 gene coated porous titanium implant surface | |
Sadeghinia et al. | Nano-hydroxy apatite/chitosan/gelatin scaffolds enriched by a combination of platelet-rich plasma and fibrin glue enhance proliferation and differentiation of seeded human dental pulp stem cells | |
Hu et al. | Small extracellular vesicles released from bioglass/hydrogel scaffold promote vascularized bone regeneration by transferring miR-23a-3p | |
Cui et al. | A pilot study of macrophage responses to silk fibroin particles | |
Xie et al. | Regulation of cellular behaviors of fibroblasts related to wound healing by sol–gel derived bioactive glass particles | |
Wang et al. | Enhanced osteogenesis of bone marrow stem cells cultured on hydroxyapatite/collagen I scaffold in the presence of low-frequency magnetic field | |
Shen et al. | bFGF-loaded mesoporous silica nanoparticles promote bone regeneration through the wnt/β-catenin signalling pathway | |
Zhang et al. | Platelet‐derived growth factor BB gene‐released scaffolds: biosynthesis and characterization | |
Dutta et al. | Unraveling the potential of 3D bioprinted immunomodulatory materials for regulating macrophage polarization: State-of-the-art in bone and associated tissue regeneration | |
Yi et al. | Effects of electromagnetic field frequencies on chondrocytes in 3D cell‐printed composite constructs | |
Lee et al. | Intracellular delivery of recombinant RUNX2 facilitated by cell-penetrating protein for the osteogenic differentiation of hMSCs | |
Li et al. | “Genetic scissors” CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair | |
Ma et al. | Effect of a synthetic link N peptide nanofiber scaffold on the matrix deposition of aggrecan and type II collagen in rabbit notochordal cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150401 |